EUCTR2017-004579-29-BE进行中（未招募）1 期
Gastrointestinal behavior of atazanavir in healthy volunteers
KU Leuven Drug Delivery & Disposition0 个研究点目标入组 15 人开始时间: 2018年1月23日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Healthy volunteers
- •- Age between 18 and 40 years old
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Acute/chronic GI condition
- •- Use of medication
- •- Pregnancy
- •- frequent exposure to X-rays during the past year
- •- HIV / HBV / HCV infection
研究者
相似试验
进行中（未招募）
1 期
Pharmacocinétique de l’atazanavir chez des patients infectés par le VIH, traités en première ligne par l’association atazanavir+ritonavir et emtricitabine+ténofovir en prise unique. - COPHAR-3EUCTR2007-003203-12-FRAgence nationale de recherches sur le sida et les hépatites virales. ANRS
进行中（未招募）
1 期
Gastrointestinal behavior of tenofovir DF in healthy volunteersEUCTR2011-005863-25-BEKatholieke Universiteit Leuven - Pharmacotechnology and Biopharmacy5
已完成
不适用
The effects of atazanavir-induced hyperbilirubinemia during human endotoxemia.Blood poisoning1000401810011954sepsisNL-OMON33311niversitair Medisch Centrum Sint Radboud20
进行中（未招募）
1 期
Exploring how the tablet Noxafil reacts in the human body after oral intake•Administering one tablet of Noxafil with a glass of 240 ml of water•Administering four tablets of Noxafil with a glass of 240 ml of water•Administering one tablet of Noxafil with a glass of 240 ml of water, prior to the intake of 400 ml Ensure plus (liquid meal)•Administering four tablets of Noxafil with a glass of 240 ml of water, prior to the intake of 400 ml Ensure plus (liquid meal)EUCTR2015-002703-28-BEKU Leuven - Drug Delivery & Disposition5
进行中（未招募）
不适用
Pharmacokinetics of atazanavir at the dose of 300mg or 400mg in subjects with HIV-1 infection and non-decompensated hepatic cirrhosis (Child-Pugh A o B, Metavir F4), crossover study. - EPAZANAVIR-1EUCTR2007-005330-37-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)